Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial

Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial

Abstract Background A 12-week, double-blind, parallel, multi-center randomized controlled trial in 316 adult patients with major depressive disorder (MDD) was conducted to evaluate the effectiveness of pharmacogenetic (PGx) testing for drug therapy guidance. Methods Patients with a CGI-S ≥ 4 and req...

Full description

Bibliographic Details
Main Authors: Víctor Pérez, Ariana Salavert, Jordi Espadaler, Miquel Tuson, Jerónimo Saiz-Ruiz, Cristina Sáez-Navarro, Julio Bobes, Enrique Baca-García, Eduard Vieta, José M. Olivares, Roberto Rodriguez-Jimenez, José M. Villagrán, Josep Gascón, Josep Cañete-Crespillo, Montse Solé, Pilar A. Saiz, Ángela Ibáñez, Javier de Diego-Adeliño, AB-GEN Collaborative Group, José M. Menchón
Format: Article
Language:English
Published: BMC 2017-07-01
Series:BMC Psychiatry
Subjects:
Depression
Pharmacogenetics
Precision medicine
Antidepressant response
Randomized clinical trial
Online Access:http://link.springer.com/article/10.1186/s12888-017-1412-1

Internet

http://link.springer.com/article/10.1186/s12888-017-1412-1

Similar Items